{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:43:35Z","timestamp":1761767015361,"version":"3.44.0"},"reference-count":23,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/07853890.2021.2012589","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T04:40:41Z","timestamp":1640925641000},"page":"108-120","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Drug-induced liver injury by glecaprevir\/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis"],"prefix":"10.1080","volume":"54","author":[{"given":"Hsuan-Yu","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ditmanson medical foundation Chia-Yi Christian Hospital","place":["Chiayi City, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Liang","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Zouying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5295-6667","authenticated-orcid":false,"given":"Chia-Lung","family":"Shih","sequence":"additional","affiliation":[{"name":"Clinical Medicine Research Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital","place":["Chia-Yi, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Master Program in Clinical Pharmacy, School of Pharmacy, Kaohsiung Medical University","place":["Kaohsiung, Taiwan"]},{"name":"Department of Pharmacy, Kaohsiung Medical University Hospital","place":["Kaohsiung, Taiwan"]},{"name":"Department of Medical Research, Kaohsiung Medical University Hospital","place":["Kaohsiung, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_3_4_2_1","DOI":"10.1016\/S2468-1253(20)30086-8"},{"doi-asserted-by":"crossref","unstructured":"Zeuzem S Foster GR Wang S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV Genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354\u2013369.","key":"e_1_3_4_3_1","DOI":"10.1056\/NEJMoa1702417"},{"doi-asserted-by":"crossref","unstructured":"Gane E Poordad F Zadeikis N et al. Safety and pharmacokinetics of Glecaprevir\/Pibrentasvir in adults with chronic Genotype 1-6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657\u20131664.","key":"e_1_3_4_4_1","DOI":"10.1093\/cid\/ciz022"},{"unstructured":"FDA. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret Zepatier and Vosevi in some patients with advanced liver disease. [cited 2021 May 12]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warnsabout-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and5.","key":"e_1_3_4_5_1"},{"doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews 2021;10:89.","key":"e_1_3_4_6_1","DOI":"10.1186\/s13643-021-01626-4"},{"doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. clinical practice guideline panel: Chair: panel members EASL governing board representative. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019; 70(6):1222\u20131261.","key":"e_1_3_4_7_1","DOI":"10.1016\/j.jhep.2019.02.014"},{"doi-asserted-by":"crossref","unstructured":"Sterne JAC Savovi_c J Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","key":"e_1_3_4_8_1","DOI":"10.1136\/bmj.l4898"},{"unstructured":"OpenMeta [Analyst]. CEBM @ Brown. [cited 2021 May 19]. Available from: http:\/\/www.cebm.brown.edu\/openmeta\/index.html.","key":"e_1_3_4_9_1"},{"doi-asserted-by":"crossref","unstructured":"Asselah T Kowdley KV Zadeikis N et al. Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 4 5 or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417\u2013426.","key":"e_1_3_4_10_1","DOI":"10.1016\/j.cgh.2017.09.027"},{"doi-asserted-by":"crossref","unstructured":"Wyles D Poordad F Wang S et al. Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018;67(2):514\u2013523.","key":"e_1_3_4_11_1","DOI":"10.1002\/hep.29541"},{"doi-asserted-by":"crossref","unstructured":"Toyoda H Chayama K Suzuki F et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67(2):505\u2013513.","key":"e_1_3_4_12_1","DOI":"10.1002\/hep.29510"},{"doi-asserted-by":"publisher","key":"e_1_3_4_13_1","DOI":"10.1016\/j.jhep.2018.03.007"},{"doi-asserted-by":"publisher","key":"e_1_3_4_14_1","DOI":"10.1111\/jvh.13038"},{"doi-asserted-by":"publisher","key":"e_1_3_4_15_1","DOI":"10.1007\/s00535-017-1391-5"},{"doi-asserted-by":"crossref","unstructured":"Liu YC Jeng WJ Cheng YT et al. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine. 2020;99(37):e21898.","key":"e_1_3_4_16_1","DOI":"10.1097\/MD.0000000000021898"},{"doi-asserted-by":"crossref","unstructured":"Kumada H Suzuki Y Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083\u20132091.","key":"e_1_3_4_17_1","DOI":"10.1002\/hep.27113"},{"doi-asserted-by":"crossref","unstructured":"Forns X Lee SS Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1 2 4 5 or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm open-label multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062\u20131068.","key":"e_1_3_4_18_1","DOI":"10.1016\/S1473-3099(17)30496-6"},{"doi-asserted-by":"crossref","unstructured":"Berg T Naumann U Stoehr A et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052\u20131059.","key":"e_1_3_4_19_1","DOI":"10.1111\/apt.15222"},{"doi-asserted-by":"crossref","unstructured":"Nozaki A Atsukawa M Kondo C et al. The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14(2):225\u2013238.","key":"e_1_3_4_20_1","DOI":"10.1007\/s12072-020-10019-z"},{"doi-asserted-by":"crossref","unstructured":"Yen HH Su PY Zeng YH et al. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS One. 2020;15(8):e0237582.","key":"e_1_3_4_21_1","DOI":"10.1371\/journal.pone.0237582"},{"doi-asserted-by":"crossref","unstructured":"Gane E Lawitz E Pugatch D et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448\u20131455.","key":"e_1_3_4_22_1","DOI":"10.1056\/NEJMoa1704053"},{"doi-asserted-by":"crossref","unstructured":"Kumada H Watanabe T Suzuki F et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience severe renal impairment or genotype 3 infection. J Gastroenterol. 2018;53(4):566\u2013575.","key":"e_1_3_4_23_1","DOI":"10.1007\/s00535-017-1396-0"},{"doi-asserted-by":"crossref","unstructured":"Asselah T Lee SS Yao BB et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5 6): an open-label multicentre phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45\u201351.","key":"e_1_3_4_24_1","DOI":"10.1016\/S2468-1253(18)30341-8"}],"container-title":["Annals of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07853890.2021.2012589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:50:43Z","timestamp":1757325043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07853890.2021.2012589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,31]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/07853890.2021.2012589"],"URL":"https:\/\/doi.org\/10.1080\/07853890.2021.2012589","relation":{},"ISSN":["0785-3890","1365-2060"],"issn-type":[{"type":"print","value":"0785-3890"},{"type":"electronic","value":"1365-2060"}],"subject":[],"published":{"date-parts":[[2021,12,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iann20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}